Breakthrough Therapies for
Our mission is to discover therapies that slow, stop, or reverse neurodegenerative diseases.
Who We Are
The Neurodegeneration Consortium (NDC) is a multi-institutional research consortium mobilizing innovative investigators against neurodegenerative diseases.
The NDC unites the drug discovery capabilities of MD Anderson Cancer Center Therapeutics Discovery Division with leading neuroscientists at MIT, Mount Sinai School of Medicine, and researchers at several other institutions. Launched in 2012, the NDC is funded by the Robert A. and Renee E. Belfer family foundation, Oskar Fischer Project, and many other philanthropic donors and funding agencies.
The NDC is part of the Therapeutics Discovery Division at MD Anderson Cancer Center. This is a team of over 100 dedicated researchers, clinicians, drug developers and scientific experts that develop transformative therapies ranging from small molecule, biologics to cell therapies.
"The NDC has the opportunity to change the lives of patients suffering from neurological disorders. This is the great challenge of our time."
~Jim Ray, Ph.D.